PubRank

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Clinical Trial ID NCT01140347

PubWeight™ 33.14‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01140347

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015 2.18
2 The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2010 2.07
3 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
4 Which are the antibodies to watch in 2013? MAbs 2012 1.56
5 Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012 1.55
6 Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012 1.34
7 Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014 1.24
8 Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013 1.23
9 Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014 1.17
10 A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013 1.16
11 Antibodies to watch in 2014. MAbs 2013 1.14
12 Antibodies to watch in 2013: Mid-year update. MAbs 2013 1.13
13 Tumor stroma as targets for cancer therapy. Pharmacol Ther 2012 1.06
14 Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015 1.05
15 Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013 0.99
16 Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013 0.94
17 Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol 2015 0.86
18 Antibody phage display libraries: contributions to oncology. Int J Mol Sci 2012 0.85
19 Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010 0.84
20 Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2016 0.83
21 Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013 0.83
22 Ramucirumab: preclinical research and clinical development. Onco Targets Ther 2014 0.81
23 Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013 0.80
24 Clinical utility of ramucirumab in advanced gastric cancer. Biologics 2015 0.79
25 Tivozanib: current status and future directions in the treatment of solid tumors. Expert Opin Investig Drugs 2012 0.78
26 Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015 0.78
27 Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer 2016 0.78
28 Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap Adv Gastroenterol 2013 0.78
29 Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) 2016 0.78
30 Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncol 2016 0.76
31 Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs 2015 0.75
32 Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open 2020 0.75
33 Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 2012 0.75
Next 100